Skip to content

Testing of BCG vaccine against COVID-19

BCG revaccination of health care professionals working in the COVID-19 pandemic, a preventive strategy to improve innate immune response

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-4kjqtg
Enrollment
Unknown
Registered
2020-08-05
Start date
2020-08-05
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infections

Interventions

Randomized open clinical trial with the inclusion of 400 health professionals in direct contact with patients suspected of COVID-19. Two hundred individuals will be randomly allocated to each group.

Sponsors

Universidade Federal de Goias
Lead Sponsor
Universidade Federal de Goias
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: HW with BCG scar, adults, over 18 years old,who have negative IgM and IgG COVID-19 test, regardless of gender, dedicating at least 8 hours a week to care for individuals suspected of having COVID-19.

Exclusion criteria

Exclusion criteria: Participants with any of the following characteristics will be excluded: Individuals who have had a fever in the last 15 days; pregnant or lactating women; individuals with suspected viral infection including COVID-19 or bacterial in the past 15 days before randomization; have had a previous diagnosis of tuberculosis; has had a vaccination in the last 15 days; immunocompromised or with neutrophil count below 500 / mm3; using corticosteroids, antibiotics and chemotherapy drugs; present or have presented a solid or non-solid tumor in the last 2 years; or who are directly involved in the project.

Design outcomes

Primary

MeasureTime frame
Reduction of health problems of health care workers related to COVID-19 among individuals vaccinated with BCG, verified by clinical evaluation and laboratory exames during 180 days.;Reduction of positivity for COVID-19 through serological, molecular tests and / or clinical evaluation among individuals vaccinated with BCG.

Secondary

MeasureTime frame
innate immune response induction among individuals in the BCG vaccinated group, verified using citometric analysis of NK and neutrophils cell populations, 15-20 days after vaccination with BCG compared to day one (the day of inclusion in the study).

Countries

Brazil

Contacts

Public ContactAna Paula;André Kipnis;Kipnis

Universidade Federal de Goias;Universidade Federal de Goias

ana_kipnis@ufg.br;akipnis@ufg.br+55-062-32096174;+55-062-32096361

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 25, 2026